Area of research
Pathology and Forensic Medicine · Public Health, Environmental and Occupational Health
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Acute Lymphoblastic Leukemia research, Cutaneous lymphoproliferative disorders research, and Hepatocellular Carcinoma Treatment and Prognosis.
A phase II multicenter study of abexinostat, an oral histone deacetylase inhibitor, in patients with relapsed/refractory follicular lymphoma.
Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera� in patients with CD20-positive B-cell non-Hodgkin lymphoma
Targeted sequencing reveals the relationship between mutations and patients’ clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma
Interim results of a phase II multicenter study with the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory follicular lymphoma.
A phase II, multicenter, single-arm study of parsaclisib, a PI3Kδ inhibitor, in relapsed or refractory follicular lymphoma in China: Updated data from the study.
Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study.
Rhinocerebral mucormycosis caused by Rhizopus arrhizus var. tonkinensis